Pay in 4 interest-free payments of $8.00 Learn more
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6
or dexamethasone triggered synergistic anti-MM activity
Activating ALK mutations found in neuroblastoma are inhibited by Crizotinib and NVP-TAE684
The effect of adjuvant dimethylenastron
VER155008 also reduces full-length androgen receptor (AR-FL) and androgen receptor splice variant 7 (AR-V7) protein expression
26)17-5-6-18-19(14-17)28-12-11-27-18/h1
MLN-9708 - CAS# 1239908-20-3 60262 or dexamethasone triggered synergistic anti-MMMLN 9708, also known as ixazomib citrate, CAS No. 1239908 20 3, is a prodrug of Ixazomib (MMLN 2238). MLN 9708 is an orally bioavailable second generation proteasome inhibitor (PI) with potential antineoplastic activity. MLN 9708, after hydrolyzing to pharmacologically active MLN2238 (ixazomib), is a next generation proteasome inhibitor with demonstrated preclinical and clinical antimyeloma activity. MLN 9708, compared with bortezomib, has improved
US$ 25.00
US$ 149.99
US$ 65.00
US$ 40.00
US$ 88.50
US$ 48.35